Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines
Martina Fragni et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells
Mariya B. Sokol et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS (2019)
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
Alessia Cavo et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone
Antonio G. Gomes de Mello Martin et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
Sundhar Ramalingam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells
Lianhua Zhang et al.
CELL CYCLE (2017)
Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma
Hakan Soylu et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Stroma-induced Jagged1 expression drives PC3 prostate cancer cell migration; disparate effects of RIP-generated proteolytic fragments on cell behaviour and Notch signaling
Craig Delury et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer
Murielle Mimeault et al.
ONCOTARGET (2015)
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
Michele Iuliani et al.
ONCOTARGET (2015)
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro
Steven Pham et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Androgen Receptor Promotes the Oncogenic Function of Overexpressed Jagged1 in Prostate Cancer by Enhancing Cyclin B1 Expression via Akt Phosphorylation
Yongjiang Yu et al.
MOLECULAR CANCER RESEARCH (2014)
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia
Monique Dail et al.
NATURE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth
Yansheng Su et al.
CANCER LETTERS (2013)
N-substituted Piperazinopyridylsteroid Derivatives as Abiraterone Analogues Inhibit Growth and Induce Pro-apoptosis in Human Hormone-independent Prostate Cancer Cell Lines
Dominique Brossard et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
R. J. van Soest et al.
EUROPEAN JOURNAL OF CANCER (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Functional p53 determines docetaxel sensitivity in prostate cancer cells
Chengfei Liu et al.
PROSTATE (2013)
Therapeutic Effect of γ-Secretase Inhibition in KrasG12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK
Antonio Maraver et al.
CANCER CELL (2012)
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Juliet Richards et al.
CANCER RESEARCH (2012)
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Christine Vogel et al.
NATURE REVIEWS GENETICS (2012)
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo
J. Y. Henry et al.
PROSTATE (2012)
被撤回的出版物: Down-Regulation of Notch-1 Is Associated With Akt and FoxM1 in Inducing Cell Growth Inhibition and Apoptosis in Prostate Cancer Cells (Retracted article. See vol. 117, pg. 1962, 2016)
Zhiwei Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Drug resistance in metastatic castration-resistant prostate cancer
Bostjan Seruga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
被撤回的出版物: Down-Regulation of Notch-1 and Jagged-1 Inhibits Prostate Cancer Cell Growth, Migration and Invasion, and Induces Apoptosis Via Inactivation of Akt, mTOR, and NF-κB Signaling Pathways (Retracted article. See vol. 117, pg. 1960, 2016)
Zhiwei Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Targeted Knockdown of Notch1 Inhibits Invasion of Human Prostate Cancer Cells Concomitant with Inhibition of Matrix Metalloproteinase-9 and Urokinase Plasminogen Activator
Bilal Bin Hafeez et al.
CLINICAL CANCER RESEARCH (2009)
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Kim N. Chi et al.
EUROPEAN UROLOGY (2009)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations
Mick D. Brown et al.
PROSTATE (2007)
Notch signaling in vascular development and physiology
Thomas Gridley
DEVELOPMENT (2007)
Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1α,25-dihydroxyvitamin D3
Huei-Ju Ting et al.
CANCER LETTERS (2007)
The multifaceted role of Notch in cancer
Monideepa Roy et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression
Jarrett T. Whelan et al.
CELL CYCLE (2007)
Notch signalling and voltage-gated Na+ channel activity in human prostate cancer cells:: independent modulation of in vitro motility
N. Scorey et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2006)
被撤回的出版物: Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells (Retracted article. See vol.139,pg.2145,2016)
Yuxiang Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation
XD Wang et al.
DEVELOPMENTAL BIOLOGY (2006)
NOTCH signaling as a novel cancer therapeutic target
L. Miele et al.
CURRENT CANCER DRUG TARGETS (2006)
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
G Attard et al.
BJU INTERNATIONAL (2005)
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia
AP Weng et al.
SCIENCE (2004)
The role of Notch in tumorigenesis: Oncogene or tumour suppressor?
F Radtke et al.
NATURE REVIEWS CANCER (2003)
Comparative analysis of the human and mouse Hey1 promoter:: Hey genes are new notch target genes
MM Maier et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
